Supriya Lifescience Limited (IN:SUPRIYA)
:SUPRIYA
Top Page
Supriya Lifescience Limited
(SUPRIYA)
Select Model
Select Model
Rating:68Neutral
Price Target:
₹633.00
▼(-15.71% Downside)
Action:DowngradedDate:03/10/26
The score is driven primarily by strong financial performance (growth, improving profitability, and reduced leverage), partly offset by very weak technical momentum (below key moving averages with bearish MACD) and a valuation that looks relatively expensive with a low dividend yield.
Positive Factors
Revenue and Profit Growth
Sustained revenue growth and a 27% net margin show consistent demand and improving operational efficiency. Durable profitability supports reinvestment in capacity and quality, strengthens customer relationships, and provides a stable earnings base to fund future growth initiatives.
Negative Factors
Free Cash Flow Volatility
Historical FCF swings indicate uneven cash available for reinvestment and returns. Such volatility complicates long-term planning for capex and dividends, increases refinancing or liquidity risk in downturns, and means recent FCF improvement may not be fully structural yet.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profit Growth
Sustained revenue growth and a 27% net margin show consistent demand and improving operational efficiency. Durable profitability supports reinvestment in capacity and quality, strengthens customer relationships, and provides a stable earnings base to fund future growth initiatives.
Read all positive factors
Supriya Lifescience Limited (SUPRIYA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹49.26B
Dividend Yield0.13%
Average Volume (3M)18.01K
Price to Earnings (P/E)30.4
Beta (1Y)1.32
Revenue Growth14.35%
EPS Growth15.79%
CountryIN
Employees448
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)6.20
Shares Outstanding80,482,800
10 Day Avg. Volume18,341
30 Day Avg. Volume18,009
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)5.91
Price to Sales (P/S)8.46
P/FCF Ratio578.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)30.65
Revenue Forecast (FY)₹10.17B
Supriya Lifescience Limited Business Overview & Revenue Model
Company Description
Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti...
How the Company Makes Money
Supriya Lifescience Limited generates revenue primarily through the sale of its active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies. The company’s revenue model is driven by both domestic and international sales,...
Supriya Lifescience Limited Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
85
Very Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.15B | 6.96B | 5.70B | 4.51B | 5.19B | 3.85B |
| Gross Profit | 4.83B | 3.84B | 2.80B | 2.80B | 2.89B | 2.34B |
| EBITDA | 2.68B | 2.71B | 1.84B | 1.37B | 2.22B | 1.77B |
| Net Income | 1.82B | 1.88B | 1.19B | 898.57M | 1.52B | 1.24B |
Balance Sheet | ||||||
| Total Assets | 12.03B | 11.12B | 9.21B | 8.20B | 7.35B | 4.46B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 791.54M | 749.56M | 1.58B | 2.25B | 864.27M |
| Total Debt | 52.32M | 53.80M | 54.88M | 224.68M | 274.15M | 721.94M |
| Total Liabilities | 1.21B | 1.16B | 1.06B | 1.21B | 1.19B | 1.77B |
| Stockholders Equity | 10.82B | 9.97B | 8.15B | 6.99B | 6.16B | 2.69B |
Cash Flow | ||||||
| Free Cash Flow | 133.16M | 101.89M | -323.48M | -422.13M | -111.03M | 316.89M |
| Operating Cash Flow | 555.65M | 1.73B | 1.13B | 661.87M | 488.01M | 799.30M |
| Investing Cash Flow | -304.29M | -1.62B | -1.74B | -1.33B | -598.22M | -468.01M |
| Financing Cash Flow | -10.75M | -65.47M | -223.59M | -97.77M | 1.50B | -145.16M |
Supriya Lifescience Limited Technical Analysis
Neutral
751.00
Price Trends
648.90
Negative
700.41
Negative
697.72
Negative
Market Momentum
-20.83
Negative
48.52
Neutral
59.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUPRIYA, the sentiment is Neutral. The current price of 751 is above the 20-day moving average (MA) of 590.80, above the 50-day MA of 648.90, and above the 200-day MA of 697.72, indicating a neutral trend. The MACD of -20.83 indicates Negative momentum. The RSI at 48.52 is Neutral, neither overbought nor oversold. The STOCH value of 59.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SUPRIYA.
Supriya Lifescience Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ₹49.26B | 30.45 | ― | 0.13% | 14.35% | 15.79% | |
57 Neutral | ₹32.13B | 23.17 | ― | 0.24% | 4.08% | 31.52% | |
57 Neutral | ₹29.06B | 67.80 | ― | 0.03% | 7.78% | -34.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | ₹36.51B | -9.14 | ― | ― | ― | ― | |
41 Neutral | ₹40.37B | -13.56 | ― | ― | -0.82% | 34.67% |
* Healthcare Sector Average
IN:SUPRIYA
Supriya Lifescience Limited
612.10
-181.00
-22.82%
IN:AARTIDRUGS
Aarti Drugs Limited
352.05
5.16
1.49%
IN:GUFICBIO
Gufic Biosciences Limited
289.75
-53.01
-15.47%
IN:SPARC
Sun Pharma Advanced Research Co. Ltd.
124.40
-25.55
-17.04%
IN:SUVEN
Suven Life Sciences Limited
157.40
26.15
19.92%
Supriya Lifescience Limited Corporate Events
Supriya Lifescience Closes Trading Window Ahead of Q3 FY26 Results
Dec 28, 2025
Supriya Lifescience Limited has announced the closure of its trading window for company securities for all insiders and designated persons, including their immediate relatives, in line with SEBI (Prohibition of Insider Trading) Regulations, 2015 a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.